BioAI Health and Genomic Testing Cooperative (GTC) have partnered to leverage their AI capabilities to create advanced solutions for oncology diagnostics and clinical research. Under the partnership, GTC will become an early technology access member of BioAI's global clinical laboratories.
The collaboration involves GTC providing BioAI access to its characterized imaging data, enabling BioAI to refine and develop its AI algorithms. It also focuses on the joint development of genomic biomarker screening algorithms and assays for use in clinical settings and introduces a range of diagnostic solutions, including screening tests and comprehensive genomic profiling using DNA and RNA for tissue and liquid biopsies.
BioAI Health is a biotechnology company that leverages advanced AI for precision medicine. It focuses on mapping the causal biology of diseases, developing digital biomarkers, and identifying novel drug targets. Its key offerings include AI-driven biomarker services, drug discovery, and data sourcing. BioAI uses technological platforms such as PredictX and In-Silico Phenotype Projection to enhance genetic mutation identification and drug target discovery, helping to accelerate the clinical R&D process.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.